Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension

American Heart Journal

Volumn 152, Issue 2, 2006, Pages 246-252

  Janardhanan, Rajesh ^a   Daley, William L ^b   Naqvi, Tasneem Z ^c   Mulvagh, Sharon L ^d   Aurigemma, Gerard ^e   Zile, Michael ^f   Arnold, J Malcolm O ^g   Artis, Eunice ^b   Purkayastha, Das ^b   Thomas, James D ^h   Solomon, Scott D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; PLACEBO; VALSARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEART MUSCLE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MITRAL VALVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; COMORBIDITY; DIASTOLE; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION;

EID: 33746257174     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.01.009     Document Type: Article

References (43)

1. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
2. Gaasch W.H., and Zile M.R. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 55 (2004) 373-394
3. Aurigemma G.P., and Gaasch W.H. Diastolic heart failure. N Engl J Med 351 (2004) 1097-1105
4. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
5. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002) 1387-1393
6. Zile M.R., Baicu C.F., and Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004) 1953-1959
7. European Study Group. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 19 (1998) 990-1003
8. Aurigemma G.P., Gottdiener J.S., Shemanski L., et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 37 (2001) 1042-1048
9. Vasan R.S., and Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 156 (1996) 1789-1796
10. Corea L., Cardoni O., Fogari R., et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 60 (1996) 341-346
11. Thurmann P.A., Kenedi P., Schmidt A., et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 98 (1998) 2037-2042
12. Munagala V.K., Jacobsen S.J., Mahoney D.W., et al. Association of newer diastolic function parameters with age in healthy subjects: a population-based study. J Am Soc Echocardiogr 16 (2003) 1049-1056
13. Nagueh S.F., Middleton K.J., Kopelen H.A., et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 (1997) 1527-1533
14. Tei C., Ling L.H., Hodge D.O., et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 26 (1995) 357-366
15. Garcia M.J., Smedira N.G., Greenberg N.L., et al. Color M-mode Doppler flow propagation velocity is a preload insensitive index of left ventricular relaxation: animal and human validation. J Am Coll Cardiol 35 (2000) 201-208
16. Brun P., Tribouilloy C., Duval A.M., et al. Left ventricular flow propagation during early filling is related to wall relaxation: a color M-mode Doppler analysis. J Am Coll Cardiol 20 (1992) 420-432
17. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
18. Oki T., Tabata T., Yamada H., et al. Left ventricular diastolic properties of hypertensive patients measured by pulsed tissue Doppler imaging. J Am Soc Echocardiogr 11 (1998) 1106-1112
19. Wachtell K., Smith G., Gerdts E., et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol 85 (2000) 466-472
20. Kannel W.B., Gordon T., Castelli W.P., et al. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern Med 72 (1970) 813-822
21. Kannel W.B., Levy D., and Cupples L.A. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 10 Suppl 6 (1987) S135-S140
22. Smith V.E., White W.B., Meeran M.K., et al. Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension. J Am Coll Cardiol 8 (1986) 1449-1454
23. Ho C.Y., Sweitzer N.K., McDonough B., et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105 (2002) 2992-2997
24. Wachtell K., Bella J.N., Rokkedal J., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105 (2002) 1071-1076
25. Okin P.M., Devereux R.B., Jern S., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292 (2004) 2343-2349
26. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 (1998) 48-54
27. Devereux R.B., Wachtell K., Gerdts E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004) 2350-2356
28. Nishimura R.A., and Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 30 (1997) 8-18
29. Schillaci G., Pasqualini L., Verdecchia P., et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 39 (2002) 2005-2011
30. Ishida Y., Meisner J.S., Tsujioka K., et al. Left ventricular filling dynamics: influence of left ventricular relaxation and left atrial pressure. Circulation 74 (1986) 187-196
31. Choong C.Y., Herrmann H.C., Weyman A.E., et al. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol 10 (1987) 800-808
32. Waggoner A.D., and Bierig S.M. Tissue Doppler imaging: a useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr 14 (2001) 1143-1152
33. Rodriguez L., Garcia M., Ares M., et al. Assessment of mitral annular dynamics during diastole by Doppler tissue imaging: comparison with mitral Doppler inflow in subjects without heart disease and in patients with left ventricular hypertrophy. Am Heart J 131 (1996) 982-987
34. Sohn D.W., Chai I.H., Lee D.J., et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 30 (1997) 474-480
35. Rivas-Gotz C., Manolios M., Thohan V., et al. Impact of left ventricular ejection fraction on estimation of left ventricular filling pressures using tissue Doppler and flow propagation velocity. Am J Cardiol 91 (2003) 780-784
36. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
37. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
38. Yamamoto K., Masuyama T., Sakata Y., et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 47 (2000) 274-283
39. Haber H.L., Powers E.R., Gimple L.W., et al. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 89 (1994) 2616-2625
40. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
41. Devereux R.B., Dahlof B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 110 (2004) 1456-1462
42. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002) 2512-2517
43. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362 (2003) 777-781